Beneath the Surface

About Beneath the Surface

A Healio podcast hosted by Joel M. Gelfand, MD, discussing the latest news and hot topics in the field of dermatology.

Publisher

Joel M. Gelfand, MD

Category

health & fitness · health & fitness

Language

en

Explicit

No

First episode

7 May 2025

Latest episode

10 Jul 2026

Latest episodes

14 episodes in the feed.

1. 

   10 Jul 2026

   Ready for summer: Effective sunscreen use, refuting common myths

   In this episode, guest Adewole S. Adamson, MD, MPP, discusses use of sunscreen, outlines how to decipher labels and debunks myths surrounding sunscreen. ·       Who should wear sunscreen, and when should they put it on? 1:16 ·       What ingredients should consumers look for on a sunscreen label? 5:37 ·       How can you differentiate between chemical and physical sunscreens? 7:27 ·       What are the current and upcoming innovations in sunscreens? 8:34 ·       What are some myths and controversies surrounding sunscreen? 9:44 ·       What excites you about sunscreen now? 16:13 For more, be sure to visit the Beneath the Surface video blog on Healio.com. We'd love to hear from you! Send your comments/questions to Dr. Gelfand at podcasts@healio.com (mailto:podcasts@healio.com). Follow Dr. Gelfand on LinkedIn. Dr. Adamson can be reached at adewole.adamson@austin.utexas.edu (mailto:adewole.adamson@austin.utexas.edu) or on Instagram @adeadamsonmd. Gelfand is Chief Medical Editor of Healio Dermatology. Adamson reports no relevant financial disclosures.

2. 

   5 Jun 2026

   Live from AAD 2026: New treatment data for patients with PsA, obesity

   In this episode, guest Joseph F. Merola, MD, discusses the results of the TOGETHER-PsA trial and explores combination therapy as an integrated approach to psoriatic arthritis (PsA) management. ·       What is the role of obesity in PsA?  0:55 ·       Dr. Merola discusses findings from the TOGETHER-PsA trial. 2:11 ·       Is the difference clinically meaningful to you as a rheumatologist? 4:16 ·       For patients today, would you combine tirzepatide with ixekizumab as a form of standard care? 5:13 Joseph Merola, MD, MMSc, is professor and chair of the department of dermatology, professor of internal medicine in the division of rheumatic diseases and professor in the UT Southwestern O'Donnell School of Public Health. We'd love to hear from you! Send your comments/questions to Dr. Gelfand at podcasts@healio.com (mailto:podcasts@healio.com). Follow Dr. Gelfand on LinkedIn. Dr. Merola can be reached at joseph.merola@utsouthwestern.edu. For more, be sure to visit the Beneath the Surface video blog on Healio.com. Disclosures: Eli Lilly sponsored TOGETHER-PsA. Gelfand is Chief Medical Editor of Healio Dermatology. Merola reports receiving consultant fees from AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Incyte, Janssen, Leo Pharma, MoonLake Immunotherapeutics, Novartis, Pfizer, Sanofi-Regeneron and UCB; and grant or research support from Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, MoonLake Immunotherapeutics, Sanofi-Regeneron, Sun Pharma and UCB. References: ·        Merola JF, et al. Arthritis Rheumatol. 2026;doi:10.1002/art.70134. ·        Merola JF, et al. Late-breaking research: Session 2. Presented at: American Academy of Dermatology Annual Meeting; March 27-31, 2026; Denver.

3. 

   1 May 2026

   Diagnosing, treating complex wounds with Robert Kirsner, MD, PhD

   In this episode, guest Robert Kirsner, MD, PhD, discusses clinical approaches to diagnosing chronic wounds, advancements and methods for treating them. ·       Intro 0:28 ·       Robert Kirsner, MD, PhD 0:35 ·       From a public health perspective, how big of a problem are chronic wounds?  0:59 ·       What is your clinical approach to define and evaluate chronic wounds? 2:06 ·       What imaging do you order for patients with lower extremity wounds? 4:58 ·       What advancements are we seeing in wound healing? 6:46 ·       What are some of the differential diagnoses that can generate chronic wounds in patients? 8:25 ·       Can you describe your technique for biopsy? 9:37 ·       Are there situations where you should avoid biopsy? 10:27 ·       Does a diagnosis of exclusion such as pyoderma gangrenosum (PG) need to be biopsied? 11:30 ·       Are retinoids like acitretin commonly used? 11:39 ·       What is your approach to patients with PG? 12:30 ·       Are there other immune targets that you're excited about for PG? 14:28 ·       Thanks for listening. 15:29 Robert Kirsner, MD, PhD, is chairman and professor in the department of dermatology and cutaneous surgery at University of Miami Miller School of Medicine, director of the University of Miami Hospital and Clinics Wound Center and a past vice president of the American Academy of Dermatology. We'd love to hear from you! Send your comments/questions to Dr. Gelfand at podcasts@healio.com (mailto:podcasts@healio.com). Follow Dr. Gelfand on LinkedIn. Dr. Kirsner can be reached at rkirsner@med.miami.edu. For more, be sure to visit the Beneath the Surface video blog on Healio.com. Disclosures: Gelfand is Chief Medical Editor of Healio Dermatology. Kirsner reports receiving advisory board or consultant fees from AbbVie, BPGbio, Kerecis, Leo Pharma, Organogenesis, Smith & Nephew and Urgo and grant or research support from Boehringer Ingelheim and MediWound. References: ·        Pyoderma gangrenosum. https://my.clevelandclinic.org/health/diseases/17825-pyoderma-gangrenosum-pg. Updated May 13, 2022. Accessed Feb. 25, 2026.

4. 

   3 Apr 2026

   Diagnosing, treating and managing hidradenitis suppurativa with Lauren Orenstein, MD

   In this episode, guest Lauren Orenstein, MD, MSc, discusses the challenge of diagnosing hidradenitis suppurativa, the range of therapies and pain management for patients. ·       Intro 0:28 ·       Lauren Orenstein, MD, MSc 0:37 ·       What is HS, and how is it diagnosed?  0:57 ·       Is there a differential diagnosis? 2:11 ·       Who develops HS, and why does it develop? 3:16 ·       Are there biological explanations for this patient distribution in the US?  3:54 ·       Are there any underlying genetic or environmental factors contributing to the prevalence of HS by race in the US? 4:50 ·       How much of an impact do hormones have on diagnosis? 5:37 ·       What role does age play in diagnosis? 6:45 ·       Tell us about your approach to this disease. 9:30 ·       Are retinoids like acitretin commonly used? 11:39 ·       How do you choose which biologic therapy to use for management of HS? 12:25 ·       Are there striking differences in findings between different biologics? 14:50 ·       Can you explain what deroofing is and when a patient should undergo this procedure? 15:25 ·       How do you do this procedure clinically in your practice? 19:17 ·       How do you manage the pain aspect of HS? 20:31 ·       Do people have rebounds coming off prednisone? 23:57 ·       What about patients with chronic pain? 24:46 ·       Thanks for listening. 28:11 Lauren Orenstein, MD, MSc, is an assistant professor in the department of dermatology at Emory University and staff physician at Grady Memorial Hospital. We'd love to hear from you! Send your comments/questions to Dr. Gelfand at podcasts@healio.com (mailto:podcasts@healio.com). Follow Dr. Gelfand on LinkedIn. Dr. Orenstein can be reached at lauren.orenstein@emory.edu (mailto:lauren.orenstein@emory.edu). For more, be sure to visit the Beneath the Surface video blog on Healio.com. Disclosures: Gelfand is Chief Medical Editor of Healio Dermatology. Orenstein reports financial relationships with Incyte, Novartis, Pfizer and UCB Pharma and is a member of the board of directors for the HS Foundation.

5. 

   6 Mar 2026

   The emerging role of GLP-1s in inflammatory diseases

   In this episode, guests Fatima Stanford, MD, MPH, and Philip Mease, MD, discuss the role of GLP-1s in inflammatory diseases, determining who and how these medications should be prescribed and more. ·       Intro 0:28 ·       Fatima C. Stanford, MD, MPH, MPA, MBA, MACP, FAAP, FAHA, FAMWA, FTOS, and Philip J. Mease, MD 0:37 ·       Fatima, from your expert perspective, how did we get here with GLP-1 usage, and where is the field going?  1:12 ·       Have these medications reached their maximum benefit for patients or are we going to see GLP-1 agonists improve? 2:30 ·       Philip, as a rheumatologist, can you tell us how you think about GLP-1 medications and obesity in general when approaching a rheumatic patient? 4:09 ·       Fatima, what are the best ways to approach the subject of obesity with patients?  7:46 ·       Philip, when do you broach the topic of how GLP-1s will impact patients with rheumatic disease? 11:09 ·       Which rheumatic diseases are most amenable to being improved by weight loss, GLP-1 agonism or a combination of both? 14:27 ·       Where do you see GLP-1s role in improving inflammatory diseases? 16:29 ·       Philip, what is your take on rheumatologists prescribing these medications directly? 18:43 ·       Fatima, what should those who are not experts in GLP-1 usage know about how prescribe these medications and help patients be successful on them? 21:23 ·       Are there serious side effects we need to worry about? 24:57 ·       Are there things you check before starting someone on a GLP-1 medication, or monitor while they are on one? 26:24 ·       Discussion on advisements on when to be NPO in preparation for surgery while taking these medications. 28:00 ·       Final thoughts: Where do you see the future going in this field of medicine? 29:46 ·       Thanks for listening. 32:39 Fatima C. Stanford, MD, MPH, MPA, MBA, MACP, FAAP, FAHA, FAMWA, FTOS, is an obesity medicine physician scientist at Massachusetts General Hospital and Harvard Medical School. Philip J. Mease, MD, is director of rheumatology research at Swedish Medical Center/Providence St. Joseph Health and a clinical professor at the University of Washington School of Medicine in Seattle. We'd love to hear from you! Send your comments/questions to Dr. Gelfand at podcasts@healio.com (mailto:podcasts@healio.com). Follow Dr. Gelfand on LinkedIn. For more, be sure to visit the Beneath the Surface video blog on Healio.com. Disclosures: Gelfand is Chief Medical Editor of Healio Dermatology. Mease reports receiving research grants, consultant fees and/or speaker honoraria from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Century, Cullinan, Eli Lilly, Immagene, Janssen, Moonlake Pharma, Novartis, Pfizer, Spyre, Takeda and UCB. Stanford reports consulting for Boehringer Ingelheim, Currax, Eli Lilly, Gelesis, Novo Nordisk, Pfizer and Rhythm Pharmaceuticals and serving on advisory boards for Eli Lilly and Novo Nordisk.

6. 

   6 Feb 2026

   How to recognize and diagnose measles with Amy Paller, MD

   In this episode, guest Amy S. Paller, MD, MS, discusses warning signs of measles, protocols physicians should take and more. ·       Intro 0:28 ·       Amy S. Paller, MD, MS 0:38 ·       Can you give us your perspective as a clinician on what the presentation of measles is, and what clinicians should think about this? 1:49 ·       How would you diagnose measles?  4:43 ·       How long is the quarantine period for those who have been exposed to a case of measles? 6:13 ·       Gelfand and Paller on measles exposure and vaccination status.  7:30 ·       What is the treatment for measles? 8:34 ·       Gelfand and Paller on newborns' vulnerability to this disease. 10:07 ·       How much is temporary immune amnesia going to be a problem for people who experience more susceptibility after being diagnosed with measles? 12:28 ·       Thanks for listening. 13:20 Amy S. Paller, MD, MS, is the Walter J. Hamlin professor and chair of dermatology and professor of pediatrics and director of the Skin Biology and Diseases Resource-based Center at Northwestern University's Feinberg School of Medicine. We'd love to hear from you! Send your comments/questions to Dr. Gelfand at podcasts@healio.com (mailto:podcasts@healio.com). Follow Dr. Gelfand on LinkedIn. For more, be sure to visit the Beneath the Surface video blog on Healio.com. Disclosures: Gelfand is Chief Medical Editor of Healio Dermatology. Paller reports having investigator roles with AbbVie, BioMendics, Dermavant, Eli Lilly, Incyte, Johnson & Johnson Innovative Medicine, Regeneron and UCB; consulting roles with Abeona, Arcutis, BioCryst, Boehringer-Ingelheim, Castle Creek, Chiesi, Dermavant, Johnson & Johnson Innovative Medicine, Krystal, LEO Pharma, Lilly, L'Oreal, MoonLake Immunotherapeutics, Pelthos, Quoin, Regeneron and Sanofi; and data safety monitoring board roles with AbbVie, Abeona, BioCryst, Daiichi, Sankyo and Galderma.

7. 

   5 Dec 2025

   Navigating the rapidly changing world of dermatology with Susan Taylor, MD, FAAD

   In this episode, guest and AAD president, Susan C Taylor, MD, FAAD, discusses keeping up with dermatologic innovations, advocacy in the field and more. •    Intro 0:28 •    Susan C Taylor, MD, FAAD 0:34 •    How can dermatologists get involved with the AAD? 1:03 •    What is the path forward for dermatologists as we adapt to this rapidly changing world of new employment models, technologies and AI? […] What is the AAD doing to help people navigate these changes?  3:22 •    Gelfand and Taylor discuss the AAD's Late-Breaking Research Program.  5:57 •    What initially got you into the field of dermatology?  6:45 •    What is it like when you go to Washington DC to meet with representatives? What is their perception of dermatology as a field, and how do you help them understand the importance of what we do? 10:35 •    Thanks for listening. 13:02 Susan C Taylor, MD, FAAD, is president of the American Academy of Dermatology. We'd love to hear from you! Send your comments/questions to Dr. Gelfand at podcasts@healio.com. Follow Dr. Gelfand on LinkedIn. For more, be sure to visit the Beneath the Surface video blog on Healio.com. Disclosures: Gelfand is Chief Medical Editor of Healio Dermatology. Taylor is president of the AAD.

8. 

   7 Nov 2025

   Exploring the connections between skin, cardiovascular disorders with Brittany Weber, MD, PhD

   In this episode, guest Brittany Weber, MD, PhD, FACC, FASNC, discusses the role inflammatory diseases have on cardiometabolic disorders, evaluating patients with inflammatory disease for cardiovascular risks and more. •    Intro 0:28 •    Brittany Weber, MD, PhD, FACC, FASNC 0:39 •    Why has the role of inflammatory diseases in cardiovascular conditions become the focus of your clinical work and research?  1:07 •    Can you tell us about your recent study on cardiovascular complications in women with psoriasis who are giving birth?  2:57 •    What do you recommend dermatologists tell pregnant patients with psoriasis?  4:45 •    How do you approach cardiovascular risk assessment in people with psoriasis?  6:54 •    Which patients do you decide to send to a preventative cardiologist? 10:25 •    What is a coronary calcium score test, and how does a patient get it? 11:52 •    Thank you, Dr. Weber. 15:14 Brittany Weber, MD, PhD, FACC, FASNC, is the director of the Cardio-Rheumatology Clinic at Brigham and Women's Hospital and assistant professor at Harvard Medical School. We'd love to hear from you! Send your comments/questions to Dr. Gelfand at podcasts@healio.com. Follow Dr. Gelfand on LinkedIn. For more, be sure to visit the Beneath the Surface video blog on Healio.com. Disclosures: Gelfand reports no relevant financial disclosures. Weber reports being a consultant and/or scientific advisor for BMS, Horizon, Kiniksa and Novo Nordisk.

9. 

   1 Oct 2025

   Discussing possible JAK-inhibition, Down syndrome link with Emma Guttman-Yassky, MD, PhD

   In this episode, guest Emma Guttman-Yassky, MD, PhD, discusses inflammatory diseases, the association between JAK inhibition and Down syndrome comorbidities and more. •    Intro 0:26 •    Emma Guttman-Yassky, MD, PhD 0:33 •    What is your new research in alopecia areata about, and what dermatologists should know about using dupilumab (Dupixent; Regeneron, Sanofi) in children with alopecia areata? 1:06 •    Have you tried any other drugs to target IL-13?  3:21 •    Do you think any of the currently available IL-13 targeting drugs would be useful in this setting, or do you need IL-4 targeting drugs as well?  4:22 •    Can you give some insight on the work you are doing surrounding the association between JAK inhibitors and patients with Down syndrome?  5:20 •    Do you think that the type of psoriasis we see in patients with Down syndrome may be amenable to JAK inhibitors? 6:35 •    What are some of your top tips for people who are or want to be leaders in this specialty in order to be successful? 7:53 •    Thank you, Dr. Guttman. 9:41 Emma Guttman-Yassky, MD, PhD, is the Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of Dermatology and director of the Center of Excellence in Eczema and the Laboratory of Inflammatory Skin Diseases at the Icahn School of Medicine at Mount Sinai as well as a member of the Healio Allergy/Asthma Peer Perspective Board. We’d love to hear from you! Send your comments/questions to Dr. Gelfand at podcasts@healio.com. Follow Dr. Gelfand on LinkedIn. For more, be sure to visit the Beneath the Surface video blog on Healio.com. Disclosures: Gelfand reports no relevant financial disclosures. Guttman-Yassky reports having financial relationships with AbbVie, Almirall, Amgen, AnaptysBio, Arena, Asana Biosciences, Aslan Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol Meyers Squibb, Cara Therapeutics, Celgene, Connect Pharma, Eli Lilly, EMD Serono, Evidera, Galderma, Ichnos Sciences, Incyte, Innovaderm, Janssen Biotech, Kyowa Kirin, LEO Pharma, Novartis, Pandion Therapeutics, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Sanofi, SATO Pharmaceutical, Siolta Therapeutics, Target Pharma Solutions, UCB and Ventyx Biosciences.

10. 

    3 Sept 2025

    A deep dive into iPledge changes with John Barbieri, MD

    In this episode, guest John Barbieri, MD, MBA, discusses the FDA’s 2023 proposed changes to the iPledge system and the impacts of clinical trials and treatments on patients with hormonal acne. •    Intro 0:28 •    John Barbieri, MD, MBA 0:42 •    What does it mean to have a conditional recommendation, and why is this considered “controversial”?  1:50 •    What are the reasons, such as limitations of use, that lead to a conditional recommendation?  2:48 •    How would you implement these care guidelines into clinical practice?  3:53 •    Why is a medication like minocycline in the conditional category relative to other medications?  5:55 •    Tell us about some of the recent studies on spironolactone that have come out of the UK and France, and what we’ve learned from them. 7:10 •    Did they monitor any lab tests during these studies? 9:57 •    Can you tell us about the NIH-funded trial you are leading in the US? 10:36 •    Who uses spironolactone? How do you start this drug? 11:38 •    What is currently happening with iPledge? 13:04 •    How will these changes work operationally? What kind of home pregnancy test is used for patients? 15:20 •    When can clinicians expect these changes to iPledge to be implemented? 16:42 •    Thank you, Dr. Barbieri. 17:15 John Barbieri, MD, MBA, is the director of the Advanced Acne Therapeutics Clinic at Brigham and Women’s Hospital in Boston. We’d love to hear from you! Send your comments/questions to Dr. Gelfand at podcasts@healio.com. Follow Dr. Gelfand on LinkedIn. For more, be sure to visit the Beneath the Surface video blog on Healio.com. Disclosures: Gelfand and Barbieri report no relevant financial disclosures.

11. 

    6 Aug 2025

    The science behind vitiligo with John Harris, MD, PhD

    In this episode, guest John E. Harris, MD, PhD, discusses how vitiligo occurs and how dermatologists can navigate the vitiligo treatment landscape. •    Intro 0:28 •    John E. Harris, MD, PhD 0:41 •    How does vitiligo occur, and what is the basic science behind it?  1:08 •    Are there any known triggers of this condition in people who have genetic susceptibility to it?  3:19 •    How does drug-induced vitiligo occur in people?  4:42 •    When you see a patient with vitiligo, how do you approach the patient to establish a diagnosis?  6:03 •    Given that this is an autoimmune disease, do you routinely screen vitiligo patients for things like their thyroid function and B12 levels? 9:54 •    What about the pernicious anemia aspect of things? 10:36 •    Tell us a little bit about the treatment landscape, and how you counsel patients. 12:26 •    Who is a good candidate for these new treatment options, and what success rate do you quote over a period of time? 14:06 •    When do you bring patients back in for follow-ups? 14:59 •    How often are you administering combination therapy? 15:30 •    Does narrow band UVB work synergistically with other therapies, or is it more of an added measure? 16:20 •    How do you manage patients who have early extensive active vitiligo? 17:08 •    If someone has facial vitiligo in a non-pigmented area, do you still treat that patient? 18:01 •    Thank you, Dr. Harris. 19:09 John E. Harris, MD, PhD, is professor and chair of the Department of Dermatology and founding director of the Vitiligo Clinical Research Center, as well as the founding director of the Autoimmune Therapeutics Institute at UMass Chan Medical School. We’d love to hear from you! Send your comments/questions to Dr. Gelfand at podcasts@healio.com. Follow Dr. Gelfand on LinkedIn. For more, be sure to visit the Beneath the Surface video blog on Healio.com. Disclosures: Gelfand reports no relevant financial disclosures. Harris reports having financial relationships with AbbVie, Aclaris Therapeutics, Admirx, Aldena Therapeutics, Almirall, AnaptysBio, Avita, BiologicsMD, Boston Pharma, Celgene, Cogen Therapeutics, Dermavant, Dermira, EMD Serono, Expert Institute, Frazier Management, Genzyme/Sanofi, Incyte, Janssen, LEO Pharma, Methuselah Health, NIRA Biosciences, Pandion, Pfizer, Rheos Medicines, Sonoma Biotherapeutics, Stiefel/GSK, Sun Pharmaceuticals, Temprian Therapeutics, TeVido BioDevices, 3rd Rock Ventures, TWi Biotech, Villaris Therapeutics and Vimela Therapeutics.

12. 

    2 Jul 2025

    Exploring sodium’s effect on dermatologic disease with Katrina Abuabara, MD

    Katrina Abuabara, MD, explores the potential connection between sodium intake and dermatologic conditions like eczema and psoriasis, advising dermatologists on dietary recommendations in this interview.

13. 

    4 Jun 2025

    Addressing JAK inhibitor safety in alopecia with Brett King, MD, PhD

    Dermatologist Brett King, MD, PhD, discusses the effectiveness of JAK inhibitors for alopecia areata and managing patient expectations around treatment pauses in this interview.

14. 

    7 May 2025

    How to embrace AI responsibly with Roxana Daneshjou, MD, PhD

    In this episode, guest Roxana Daneshjou, MD, PhD, discusses the role of artificial intelligence in dermatology practice, and the future of AI models in medicine. •    Intro 0:29 •    Roxana Daneshjou, MD, PhD 0:45 •    What is artificial intelligence?  1:10 •    What led to this largely academic endeavor becoming deployable?  2:36 •    How is AI being deployed in health care today? 5:36 •    What is currently deployable about AI in the dermatology space? 7:56 •    How long do you think it will be before dermatologists are using AI in their typical practice? 12:23 •    Gelfand and Daneshjou on the dangers of AI models in health care.  17:06 •    How much of a concern is diversity in clinical practice when it comes to AI and how do we navigate this as clinicians?  20:28 •    Can you predict how long it will take for patients to come into a physician’s office with an AI-generated diagnosis and treatment plan?  23:18 •    Thank you, Dr. Daneshjou. 26:35 Roxana Daneshjou, MD, PhD, is an assistant professor of biomedical data science and dermatology at Standford University. We’d love to hear from you! Send your comments/questions to Dr. Gelfand at podcasts@healio.com. Follow Dr. Gelfand on LinkedIn. Daneshjou can be found @RoxanaDaneshjou on X and on Instagram. For more, be sure to revisit the Beneath the Surface video blog on Healio.com. Disclosures: Gelfand reports no relevant financial disclosures. Daneshjou reports having stock options from Revea and MDalgorithms; receiving personal fees from Pfizer, Frazier Healthcare Partners and L'Oreal outside the submitted work; having a patent pending for 17/937 714; and serving as a member of American Academy of Dermatology Augmented Intelligence Committee.

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Apple Podcasts (US)

5.0 / 5

1 ratings

Podcast Authority Score: 14 / 100

A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.

Quality

29

Social presence

0

YouTube

0

Engagement

0

Contact Beneath the Surface

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.